Search

Your search keyword '"Carrupt PA"' showing total 219 results

Search Constraints

Start Over You searched for: Author "Carrupt PA" Remove constraint Author: "Carrupt PA"
219 results on '"Carrupt PA"'

Search Results

151. [Chirality and drugs].

152. Predicting blood-brain barrier permeation from three-dimensional molecular structure.

153. Evaluation and prediction of drug permeation.

154. Combined molecular lipophilicity descriptors and their role in understanding intramolecular effects.

155. Production and characterization of 22 monoclonal antibodies directed against S 20499, a new potent 5-HT1A chiral agonist: influence of the hapten structure on specificity and stereorecognition.

156. The pH-partition profile of the anti-ischemic drug trimetazidine may explain its reduction of intracellular acidosis.

157. Monoamine oxidase inhibitor properties of some benzazoles: structure-activity relationships.

158. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites.

159. Molecular modeling of hen egg lysozyme HEL[52-61] peptide binding to I-Ak MHC class II molecule.

160. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease.

161. Inhibition of monoamine oxidase-B by condensed pyridazines and pyrimidines: effects of lipophilicity and structure-activity relationships.

162. Mechanisms of liposomes/water partitioning of (p-methylbenzyl)alkylamines.

163. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant.

164. Structure-property relationships of trimetazidine derivatives and model compounds as potential antioxidants.

165. Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore.

166. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.

168. The molecular behaviour of cetirizine.

169. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.

170. A cellular automata model of diffusion in aqueous systems.

172. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.

173. Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.

174. Esterase-like activity of human serum albumin toward prodrug esters of nicotinic acid.

175. Knowledge-based modeling of a legume lectin and docking of the carbohydrate ligand: the Ulex europaeus lectin I and its interaction with fucose.

176. A continuous fluorimetric method to monitor the enzymatic hydrolysis of medicinal esters.

177. How do antibodies and lectins recognize histo-blood group antigens? A 3D-QSAR study by comparative molecular field analysis (CoMFA).

179. Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

180. Insight into the lipophilicity of the aromatic N-oxide moiety.

181. A cellular automata model of enzyme kinetics.

182. Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

183. Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration.

184. [Molecular lipophilicity potential (MLP) in drug design. Complementing theoretical tools with experimental results].

185. Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

186. Lipophilicity in molecular modeling.

187. Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.

188. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

189. Stabilization of the hydrophilic sphere of iobitridol, an iodinated contrast agent, as revealed by experimental and computational investigations.

190. Structure-affinity relationships of baclofen and 3-heteroaromatic analogues.

191. Esters of L-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism.

192. Inhibition of monoamine oxidase-B by 5H-indeno[1,2-c]pyridazines: biological activities, quantitative structure-activity relationships (QSARs) and 3D-QSARs.

193. Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships.

194. Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

195. A cellular automata model of the hydrophobic effect.

196. Mechanism of ligand binding to alpha 1-acid glycoprotein (orosomucoid): correlated thermodynamic factors and molecular parameters of polarity.

197. Molecular lipophilicity potential, a tool in 3D QSAR: method and applications.

198. Structure-genotoxicity relationships of allylbenzenes and propenylbenzenes: a quantum chemical study.

199. Effects of solvation on the ionization and conformation of raclopride and other antidopaminergic 6-methoxysalicylamides: insight into the pharmacophore.

200. Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity.

Catalog

Books, media, physical & digital resources